Nurix Therapeutics Files 8-K
Ticker: NRIX · Form: 8-K · Filed: Sep 3, 2025 · CIK: 1549595
Sentiment: neutral
Topics: corporate-disclosure, 8-K
Related Tickers: NRIX
TL;DR
Nurix Therapeutics filed an 8-K on 9/3/25 with updated corporate info.
AI Summary
Nurix Therapeutics, Inc. filed an 8-K on September 3, 2025, reporting on Regulation FD Disclosure and Financial Statements and Exhibits. The filing details the company's principal executive offices located at 1700 Owens Street, Suite 205, San Francisco, CA 94158, and its telephone number (415) 660-5320. The company was formerly known as Nurix, Inc. and changed its name on May 9, 2012.
Why It Matters
This 8-K filing provides updated corporate information and disclosures for Nurix Therapeutics, Inc., which is important for investors and stakeholders to stay informed about the company's official details.
Risk Assessment
Risk Level: low — This filing is a routine corporate disclosure and does not contain significant financial or operational news that would inherently increase risk.
Key Players & Entities
- Nurix Therapeutics, Inc. (company) — Registrant
- September 3, 2025 (date) — Date of Report
- 1700 Owens Street, Suite 205 (address) — Principal Executive Offices
- San Francisco, California 94158 (location) — Principal Executive Offices Location
- (415) 660-5320 (phone_number) — Registrant's Telephone Number
- Nurix, Inc. (company) — Former Company Name
- May 9, 2012 (date) — Date of Name Change
FAQ
What is the primary purpose of this 8-K filing?
This 8-K filing serves as a Current Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, detailing Regulation FD Disclosure and Financial Statements and Exhibits for Nurix Therapeutics, Inc.
When was this 8-K report filed?
The report was filed on September 3, 2025.
What is Nurix Therapeutics, Inc.'s principal executive office address?
The principal executive offices are located at 1700 Owens Street, Suite 205, San Francisco, California 94158.
What was the company's former name?
The company was formerly known as Nurix, Inc.
When did Nurix Therapeutics, Inc. change its name?
The company changed its name on May 9, 2012.
Filing Stats: 646 words · 3 min read · ~2 pages · Grade level 11.7 · Accepted 2025-09-03 08:06:04
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value per share NRIX Nasdaq Global
Filing Documents
- nrix-20250903.htm (8-K) — 28KB
- nurixinvestorpresentatio.htm (EX-99.1) — 17KB
- nurixinvestorpresentatio001.jpg (GRAPHIC) — 77KB
- nurixinvestorpresentatio002.jpg (GRAPHIC) — 295KB
- nurixinvestorpresentatio003.jpg (GRAPHIC) — 87KB
- nurixinvestorpresentatio004.jpg (GRAPHIC) — 123KB
- nurixinvestorpresentatio005.jpg (GRAPHIC) — 121KB
- nurixinvestorpresentatio006.jpg (GRAPHIC) — 122KB
- nurixinvestorpresentatio007.jpg (GRAPHIC) — 143KB
- nurixinvestorpresentatio008.jpg (GRAPHIC) — 122KB
- nurixinvestorpresentatio009.jpg (GRAPHIC) — 136KB
- nurixinvestorpresentatio010.jpg (GRAPHIC) — 79KB
- nurixinvestorpresentatio011.jpg (GRAPHIC) — 104KB
- nurixinvestorpresentatio012.jpg (GRAPHIC) — 98KB
- 0001549595-25-000108.txt ( ) — 2246KB
- nrix-20250903.xsd (EX-101.SCH) — 2KB
- nrix-20250903_lab.xml (EX-101.LAB) — 22KB
- nrix-20250903_pre.xml (EX-101.PRE) — 13KB
- nrix-20250903_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. Nurix Therapeutics, Inc. (the "Company") intends to conduct meetings with securities analysts, investors and others beginning on September 3, 2025. As part of these meetings, the Company intends to utilize an investor presentation (the "Investor Presentation") which includes updates about the Company's clinical development plans for bexobrutideg (NX-5948), its investigational oral, brain-penetrant degrader of Bruton's tyrosine kinase, which is currently being evaluated in a Phase 1 clinical trial in patients with relapsed or refractory B cell malignancies. A copy of the Investor Presentation is attached hereto as Exhibit 99.1 and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in Item 7.01 of this Current Report on Form 8-K shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. In addition, the information set forth under this Item 7.01, including Exhibit 99.1, shall not be deemed an admission as to the materiality of any information in this Current Report on Form 8-K.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits The following exhibits are filed herewith and this list is intended to constitute the exhibit index: Exhibit No. Exhibit Title or Description 99.1 Nurix Therapeutics, Inc. Investor Presentation dated September 3, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NURIX THERAPEUTICS, INC. Date: September 3, 2025 By: /s/ Christine Ring Christine Ring, Ph.D., J.D. Chief Legal Officer 3